In addition to the free version becoming good enough, pharma is generally a consolidating market. My experience has been the number of companies buying software has steadily gone down. I sold software with a subscription license and the primary driver of nonrenewal was acquisition. Cubist? Acquired. Dyax? Acquired. And on and on.